77 related articles for article (PubMed ID: 16483004)
21. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
[TBL] [Abstract][Full Text] [Related]
22. Fluorescent in situ hybridization for human epidermal growth factor receptor 2 assessment in breast cancer: is it applicable as a primary test?
Arena V; Pennacchia I; Carbone A; Capelli A
J Clin Oncol; 2009 Jul; 27(19):e8; author reply e9-10. PubMed ID: 19470909
[No Abstract] [Full Text] [Related]
23. High prevalence of HER-2/neu overexpression among Iranian women with breast cancer: true or false?
Saatee S; Afrakhteh M; Sadrolhefazi B
Breast J; 2006; 12(5):499-501. PubMed ID: 16958978
[No Abstract] [Full Text] [Related]
24. The impact of HER-2 status on local recurrence in women with stage I-II breast cancer treated with breast-conserving therapy.
Harris EE; Hwang WT; Lee EA; Cengel KA; Feldman MD; Demichele A; Kao G; Solin LJ
Breast J; 2006; 12(5):431-6. PubMed ID: 16958961
[TBL] [Abstract][Full Text] [Related]
25. Importance of accurate HER2 testing in patients with metastatic breast cancer.
Gonzalez-Angulo AM
Clin Adv Hematol Oncol; 2010 Dec; 8(12):873-4. PubMed ID: 21326164
[No Abstract] [Full Text] [Related]
26. Prognostic implications of HER-2 status in steroid receptor-positive, lymph node-negative breast carcinoma.
Peiró G; Adrover E; Aranda FI; Peiró FM; Niveiro M; Sánchez-Payá J
Am J Clin Pathol; 2007 May; 127(5):780-6. PubMed ID: 17439837
[TBL] [Abstract][Full Text] [Related]
27. [Dual color in situ hybridization in HER2 testing].
Horii R
Nihon Rinsho; 2012 Sep; 70 Suppl 7():423-7. PubMed ID: 23350435
[No Abstract] [Full Text] [Related]
28. How is Her-2/neu status established when Her-2/neu and chromosome 17 centromere are both amplified?
Press MF
Am J Clin Pathol; 2006 Nov; 126(5):673-4. PubMed ID: 17050063
[No Abstract] [Full Text] [Related]
29. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray.
Shin SJ; Hyjek E; Early E; Knowles DM
Int J Surg Pathol; 2006 Oct; 14(4):279-84. PubMed ID: 17041191
[TBL] [Abstract][Full Text] [Related]
30. [Role of the FISH and CISH techniques in the analysis of HER2].
Sapino A; Gugliotta P
Pathologica; 2005 Aug; 97(4):213. PubMed ID: 16440669
[No Abstract] [Full Text] [Related]
31. Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age.
Van Mieghem T; Leunen K; Pochet N; De Moor B; De Smet F; Amant F; Berteloot P; Timmerman D; Vanden Bempt I; Drijkoningen R; Wildiers H; Paridaens R; Smeets A; Hendrickx W; Van Limbergen E; Christiaens MR; Vergote I; Neven P
Breast Cancer Res Treat; 2007 Nov; 106(1):127-33. PubMed ID: 17211534
[TBL] [Abstract][Full Text] [Related]
32. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
[TBL] [Abstract][Full Text] [Related]
33. Anthracyclines in the treatment of HER2-negative breast cancer.
Paik S; Taniyama Y; Geyer CE
J Natl Cancer Inst; 2008 Jan; 100(1):2-4. PubMed ID: 18159066
[No Abstract] [Full Text] [Related]
34. Clinical practice patterns and cost-effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients.
Fitzgibbons P; Washington MK; Murphy D
Cancer; 2010 Aug; 116(16):3980-1; author reply 3981. PubMed ID: 20564109
[No Abstract] [Full Text] [Related]
35. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
36. HER-2 amplification in tubular carcinoma of the breast.
Oakley GJ; Tubbs RR; Crowe J; Sebek B; Budd GT; Patrick RJ; Procop GW
Am J Clin Pathol; 2006 Jul; 126(1):55-8. PubMed ID: 16753605
[TBL] [Abstract][Full Text] [Related]
37. Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing service.
Faratian D; Graham A; Rae F; Thomas J
Histopathology; 2009 Mar; 54(4):428-32. PubMed ID: 19309394
[TBL] [Abstract][Full Text] [Related]
38. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
39. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
[TBL] [Abstract][Full Text] [Related]
40. Re: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
Mehta RS; Schubbert T
J Natl Cancer Inst; 2008 May; 100(9):680; author reply 680-1. PubMed ID: 18445822
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]